Flinn Sheds Light on Advances in MCL and Other Lymphomas – OncLive
OncLive |
Flinn Sheds Light on Advances in MCL and Other Lymphomas
OncLive The FDA approval of axicabtagene ciloleucel (axi-cel; Yescarta) in October 2017 for patients with non-Hodgkin lymphoma was one of the most exciting advancements in years for the lymphoma community. Investigators are building on this breakthrough by … |
